These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11117919)

  • 1. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms.
    Van den Bosch F; Kruithof E; De Vos M; De Keyser F; Mielants H
    Lancet; 2000 Nov; 356(9244):1821-2. PubMed ID: 11117919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
    Rednic S; Marinescu C; Chira R; Rogojan L; Rednic N
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):379-82. PubMed ID: 17205151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab.
    Rebelo A; Leite S; Cotter J
    BioDrugs; 2010 Dec; 24 Suppl 1():37-9. PubMed ID: 21175236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
    Generini S; Giacomelli R; Fedi R; Fulminis A; Pignone A; Frieri G; Del Rosso A; Viscido A; Galletti B; Fazzi M; Tonelli F; Matucci-Cerinic M
    Ann Rheum Dis; 2004 Dec; 63(12):1664-9. PubMed ID: 15297279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists.
    Brulhart L; Nissen MJ; Chevallier P; Gabay C
    Joint Bone Spine; 2010 Dec; 77(6):625-6. PubMed ID: 20851032
    [No Abstract]   [Full Text] [Related]  

  • 7. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for treating axial spondylarthropathy in everyday practice.
    Griffoul I; Giraudeau B; Mulleman D; Benhamou CL; Valat JP; Goupille P
    Joint Bone Spine; 2009 Jan; 76(1):39-43. PubMed ID: 19064331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of infliximab on extraintestinal manifestations of Crohn's disease.
    Kaufman I; Caspi D; Yeshurun D; Dotan I; Yaron M; Elkayam O
    Rheumatol Int; 2005 Aug; 25(6):406-10. PubMed ID: 15309501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
    Van den Bosch F; Kruithof E; Baeten D; De Keyser F; Mielants H; Veys EM
    Ann Rheum Dis; 2000 Jun; 59(6):428-33. PubMed ID: 10834859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.
    van Deventer SJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():3-8; discussion 38. PubMed ID: 10597333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.